Announced details
Adenovirus infection in immunocompromised pediatric patients; adenovirus infection after hematopoietic stem cell transplantation
The adenovirus load, which had remained above 40,000,000 IU/ml since 12 August, fell sharply and became undetectable after 3 doses of IV BCV administered from 18 August onward
The global Phase III clinical trial had enrolled 41 patients as of 15 October 2026. The targets are 69 enrolled patients by the end of 2026 and 180 by the end of 2027.
Dr. Beki James of Leeds Children’s Hospital presented a case report on BCV, which SymBio Pharmaceuticals is developing. Capital, personnel and business relationships are Not disclosed.
The location, representative and business activities of Leeds Children’s Hospital are Not disclosed. UK Paediatric BSBMTCT refers to the UK Paediatric British Society of Blood and Marrow Transplantation and Cellular Therapy. Detailed URL: https://bsbmtct.org/.
Manchester, UK (conference venue)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Case report presentation at the annual meeting of UK Paediatric BSBMTCT. Detailed URL for BSBMTCT: https://bsbmtct.org/
| Item | Details |
|---|---|
| Names of Products / Services Covered | Intravenous brincidofovir (IV BCV) / brincidofovir (BCV) |
| Counterparty | Dr. Beki James of Leeds Children’s Hospital; UK Paediatric BSBMTCT |
| Counterparty overview | The location, representative and business activities of Leeds Children’s Hospital are Not disclosed. UK Paediatric BSBMTCT refers to the UK Paediatric British Society of Blood and Marrow Transplantation and Cellular Therapy. Detailed URL: https://bsbmtct.org/. |
| Relationship with the Company | Dr. Beki James of Leeds Children’s Hospital presented a case report on BCV, which SymBio Pharmaceuticals is developing. Capital, personnel and business relationships are Not disclosed. |
| Applicable area | Adenovirus infection in immunocompromised pediatric patients; adenovirus infection after hematopoietic stem cell transplantation |
| Location | Manchester, UK (conference venue) |
| Quantitative Effects | The adenovirus load, which had remained above 40,000,000 IU/ml since 12 August, fell sharply and became undetectable after 3 doses of IV BCV administered from 18 August onward |
| Usage history | The global Phase III clinical trial had enrolled 41 patients as of 15 October 2026. The targets are 69 enrolled patients by the end of 2026 and 180 by the end of 2027. |
| Source | Case report presentation at the annual meeting of UK Paediatric BSBMTCT. Detailed URL for BSBMTCT: https://bsbmtct.org/ |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.It was a severe case in which the infection could not be controlled with existing antiviral medicines and no other approved treatment options were available.